Cartography Biosciences received FDA clearance of an IND for CBI‑1214, a T‑cell engager targeting colorectal cancer, and announced plans to initiate a Phase I trial in Q1 next year. The program also earned fast‑track designation, accelerating development timelines and potential regulatory interactions. CBI‑1214 is part of a growing wave of engineered T‑cell engager programs aiming to expand cell‑mediated immunotherapy to solid tumors. The IND clearance will enable dose‑escalation and safety characterization in humans. Investors and competitors will monitor early tolerability and any emerging biomarkers of response, which will shape go/no‑go decisions for broader development.